dockets: FDA-2026-P-5194

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id
FDA-2026-P-5194 FDA Requests that the FDA declare that the drug product Naltrexone Hydrochloride Oral Suspension, 5 mg/mL, is suitable for consideration in an Abbreviated New Drug Application. Nonrulemaking 2026-05-11T17:17:25Z 0b000064b92cf43e

Links from other tables